Home/Filings/4/0001628280-24-047155
4//SEC Filing

NEWHALL CHARLES W III 4

Accession 0001628280-24-047155

CIK 0001356576other

Filed

Nov 11, 7:00 PM ET

Accepted

Nov 12, 4:15 PM ET

Size

8.8 KB

Accession

0001628280-24-047155

Insider Transaction Report

Form 4
Period: 2024-11-11
NEWHALL CHARLES W III
Director10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2024-11-11$9.13/sh+20,000$182,600140,975 total
  • Sale

    Common Stock

    2024-11-11$36.24/sh10,700$387,768130,275 total
  • Exercise/Conversion

    Director Stock Option (Right to Buy)

    2024-11-1120,0000 total
    Exercise: $9.13From: 2016-03-03Exp: 2025-03-03Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Issuer

SUPERNUS PHARMACEUTICALS, INC.

CIK 0001356576

Entity typeother

Related Parties

1
  • filerCIK 0001005544

Filing Metadata

Form type
4
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:15 PM ET
Size
8.8 KB